Does the media favor AMRX or AVLN?

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 1 mentions for Avalyn Pharma. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Avalyn Pharma's score of 0.29 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, AVLN or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A -$21.83 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is AVLN or EWTX more profitable?

Avalyn Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Edgewise Therapeutics N/A -39.01% -36.96%

Does the media favor AVLN or EWTX?

In the previous week, Edgewise Therapeutics had 17 more articles in the media than Avalyn Pharma. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 1 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.29 beat Edgewise Therapeutics' score of -0.24 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, DFTX or AVLN?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Avalyn Pharma N/A N/A N/A -$21.83 N/A

Is DFTX or AVLN more profitable?

Avalyn Pharma's return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Avalyn Pharma N/A N/A N/A

Does the media prefer DFTX or AVLN?

In the previous week, Definium Therapeutics had 16 more articles in the media than Avalyn Pharma. MarketBeat recorded 17 mentions for Definium Therapeutics and 1 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.29 beat Definium Therapeutics' score of -0.07 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AVLN or INDV?

In the previous week, Indivior had 25 more articles in the media than Avalyn Pharma. MarketBeat recorded 26 mentions for Indivior and 1 mentions for Avalyn Pharma. Indivior's average media sentiment score of 0.87 beat Avalyn Pharma's score of 0.29 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indivior 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation and earnings, MANE or AVLN?

Veradermics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.32 N/A Avalyn Pharma N/A N/A N/A -$21.83 N/A

Is MANE or AVLN more profitable?

Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Avalyn Pharma N/A N/A N/A

Does the media prefer MANE or AVLN?

In the previous week, Veradermics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.29 beat Veradermics' score of -0.21 indicating that Avalyn Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Avalyn Pharma (AVLN) Competitors

$33.92 0.00 (0.00%)

As of 08/7/2026 04:00 PM Eastern

Compare

AVLN vs. AMRX, EWTX, DFTX, INDV, and MANE

Should you buy Avalyn Pharma stock or one of its competitors? MarketBeat compares Avalyn Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avalyn Pharma include Amneal Pharmaceuticals (AMRX), Edgewise Therapeutics (EWTX), Definium Therapeutics (DFTX), Indivior (INDV), and Veradermics (MANE). These companies are all part of the "pharmaceuticals" industry.

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Avalyn Pharma. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 1 mentions for Avalyn Pharma. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Avalyn Pharma's score of 0.29 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.92	$72.06M	$0.49	37.02
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Amneal Pharmaceuticals has a net margin of 5.05% compared to Avalyn Pharma's net margin of 0.00%. Avalyn Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Avalyn Pharma	N/A	N/A	N/A

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amneal Pharmaceuticals currently has a consensus price target of $17.67, indicating a potential downside of 2.61%. Avalyn Pharma has a consensus price target of $59.00, indicating a potential upside of 73.94%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Summary

Amneal Pharmaceuticals beats Avalyn Pharma on 10 of the 14 factors compared between the two stocks.

How does Avalyn Pharma compare to Edgewise Therapeutics?

Avalyn Pharma (NASDAQ:AVLN) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Avalyn Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Avalyn Pharma presently has a consensus price target of $59.00, indicating a potential upside of 73.94%. Edgewise Therapeutics has a consensus price target of $48.75, indicating a potential upside of 12.02%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Avalyn Pharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

In the previous week, Edgewise Therapeutics had 17 more articles in the media than Avalyn Pharma. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 1 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.29 beat Edgewise Therapeutics' score of -0.24 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalyn Pharma beats Edgewise Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Avalyn Pharma compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Avalyn Pharma's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Avalyn Pharma	N/A	N/A	N/A

Definium Therapeutics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Definium Therapeutics currently has a consensus target price of $55.00, indicating a potential upside of 19.20%. Avalyn Pharma has a consensus target price of $59.00, indicating a potential upside of 73.94%. Given Avalyn Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Avalyn Pharma is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Definium Therapeutics had 16 more articles in the media than Avalyn Pharma. MarketBeat recorded 17 mentions for Definium Therapeutics and 1 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.29 beat Definium Therapeutics' score of -0.07 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalyn Pharma beats Definium Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Avalyn Pharma compare to Indivior?

Avalyn Pharma (NASDAQ:AVLN) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Indivior has a net margin of 26.65% compared to Avalyn Pharma's net margin of 0.00%. Avalyn Pharma's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Indivior	26.65%	-283.11%	36.85%

Indivior has higher revenue and earnings than Avalyn Pharma. Avalyn Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Indivior	$1.33B	3.44	$210M	$2.79	13.91

Avalyn Pharma presently has a consensus price target of $59.00, suggesting a potential upside of 73.94%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 16.35%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalyn Pharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

60.3% of Indivior shares are owned by institutional investors. 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Indivior had 25 more articles in the media than Avalyn Pharma. MarketBeat recorded 26 mentions for Indivior and 1 mentions for Avalyn Pharma. Indivior's average media sentiment score of 0.87 beat Avalyn Pharma's score of 0.29 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Indivior beats Avalyn Pharma on 10 of the 14 factors compared between the two stocks.

How does Avalyn Pharma compare to Veradermics?

Veradermics (NYSE:MANE) and Avalyn Pharma (NASDAQ:AVLN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Veradermics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Veradermics and 1 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.29 beat Veradermics' score of -0.21 indicating that Avalyn Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.32	N/A
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A

Veradermics presently has a consensus target price of $153.00, suggesting a potential upside of 34.86%. Avalyn Pharma has a consensus target price of $59.00, suggesting a potential upside of 73.94%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Avalyn Pharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Avalyn Pharma	N/A	N/A	N/A

Summary

Avalyn Pharma beats Veradermics on 5 of the 8 factors compared between the two stocks.

Get Avalyn Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVLN vs. The Competition

Export

Metric	Avalyn Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.50B	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-1.55	790.97	270.58	25.05
Price / Sales	N/A	739.94	598.42	84.08
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	N/A	10.29	11.18	6.43
Net Income	N/A	$2.78B	$3.45B	$348.10M
7 Day Performance	19.02%	2.76%	3.37%	2.66%
1 Month Performance	20.88%	-0.65%	-0.73%	-0.85%
1 Year Performance	N/A	192.52%	77.30%	23.96%

Avalyn Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVLN Avalyn Pharma	3.581 of 5 stars	$33.92 flat	$59.00 +73.9%	N/A	$1.50B	N/A	N/A	51	Gap Down
AMRX Amneal Pharmaceuticals	3.2058 of 5 stars	$18.14 +0.4%	$17.67 -2.6%	+112.4%	$5.76B	$3.02B	37.02	8,500
EWTX Edgewise Therapeutics	2.1221 of 5 stars	$43.52 -2.0%	$48.75 +12.0%	+243.2%	$4.78B	N/A	N/A	60	News Coverage Positive News Earnings Report Analyst Revision
DFTX Definium Therapeutics	3.0108 of 5 stars	$46.14 flat	$55.00 +19.2%	+368.4%	$4.60B	N/A	N/A	40	Earnings Report Analyst Forecast
INDV Indivior	3.7188 of 5 stars	$38.82 +0.4%	$45.17 +16.3%	+76.5%	$4.56B	$1.24B	13.91	1,051	Trending News Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVLN) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalyn Pharma (AVLN) Competitors

AVLN vs. AMRX, EWTX, DFTX, INDV, and MANE

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Summary

How does Avalyn Pharma compare to Edgewise Therapeutics?

Summary

How does Avalyn Pharma compare to Definium Therapeutics?

Summary

How does Avalyn Pharma compare to Indivior?

Summary

How does Avalyn Pharma compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalyn Pharma (AVLN) Competitors

AVLN vs. AMRX, EWTX, DFTX, INDV, and MANE

How does Avalyn Pharma compare to Amneal Pharmaceuticals?

Does the media favor AMRX or AVLN?

Which has better earnings & valuation, AMRX or AVLN?

Is AMRX or AVLN more profitable?

Do insiders & institutionals believe in AMRX or AVLN?

Do analysts recommend AMRX or AVLN?

Summary

How does Avalyn Pharma compare to Edgewise Therapeutics?

Is AVLN or EWTX more profitable?

Do analysts prefer AVLN or EWTX?

Which has stronger earnings & valuation, AVLN or EWTX?

Does the media favor AVLN or EWTX?

Summary

How does Avalyn Pharma compare to Definium Therapeutics?

Do institutionals and insiders hold more shares of DFTX or AVLN?

Is DFTX or AVLN more profitable?

Which has stronger valuation & earnings, DFTX or AVLN?

Do analysts rate DFTX or AVLN?

Does the media prefer DFTX or AVLN?

Summary

How does Avalyn Pharma compare to Indivior?

Is AVLN or INDV more profitable?

Which has stronger earnings & valuation, AVLN or INDV?

Do analysts prefer AVLN or INDV?

Do institutionals and insiders have more ownership in AVLN or INDV?

Does the media prefer AVLN or INDV?

Summary

How does Avalyn Pharma compare to Veradermics?

Does the media prefer MANE or AVLN?

Which has better valuation and earnings, MANE or AVLN?

Do analysts prefer MANE or AVLN?

Is MANE or AVLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVLN vs. The Competition

Avalyn Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools